Impact of Enzyme Replacement Therapy on Cardiac Morphology and Function and Late Enhancement in Fabry's Cardiomyopathy

American Journal of Cardiology

Volumn 97, Issue 10, 2006, Pages 1515-1518

  Beer, Meinrad ^a   Weidemann, Frank ^b   Breunig, Frank ^b   Knoll, Anita ^b   Koeppe, Sabrina ^a   Machann, Wolfram ^a   Hahn, Dietbert ^a   Wanner, Christoph ^b   Strotmann, Jörg ^b   Sandstede, Jörn ^a  

^a Institut für Röntgendiagnostik   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; ALPHA-GALACTOSIDASE; CONTRAST MEDIA; ECHOCARDIOGRAPHY, DOPPLER; FABRY DISEASE; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33646173913     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.11.087     Document Type: Article

References (16)

1. Sachdev B., Takenaka T., Teraguchi H., Tei C., Lee P., McKenna W.J., and Elliott P.M. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002) 1407-1411
2. Desnick R.J., Ioannou Y.A., and Eng C.M. α-Galactosidase A deficiency. Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. (2001), McGraw-Hill, New York, New York 3733-3774
3. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., Petrou M., and Pennell D.J. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
4. Moon J.C.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., Leed P.J., and Elliott P.M. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (2003) 2151-2155
5. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J., and International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
6. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. Enzyme replacement therapy in Fabry disease. a randomized controlled trial. JAMA 285 (2001) 2743-2749
7. Weidemann F., Breunig F., Beer M., Sandstede J., Turschner O., Voelker W., Ertl G., Knoll A., Wanner C., and Strotmann J.M. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease. a prospective strain rate imaging study. Circulation 108 (2003) 1299-1301
8. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., and Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder. expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138 (2003) 338-346
9. Sandstede J.J., Pabst T., Beer M., Lipke C., Baurle K., Butter F., Harre K., Kenn W., Voelker W., Neubauer S., and Hahn D. Assessment of myocardial infarction in humans with (23) Na MR imaging. comparison with cine MR imaging and delayed contrast enhancement. Radiology 221 (2001) 222-228
10. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., Pennell D.J., Rumberger J.A., Ryan T., Verani M.S., and American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
11. Bogaert J., Goldstein M., Tannouri F., Golzarian J., and Dymarkowski S. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. Am J Roentgenol 180 (2003) 981-985
12. McCrohon J.A., Moon J.C., Prasad S.K., McKenna W.J., Lorenz C.H., Coats A.J., and Pennell D.J. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003) 54-59
13. Teraoka K., Hirano M., Ookubo H., Sasaki K., Katsuyama H., Amino M., Abe Y., and Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Mag Reson Med 22 (2004) 155-161
14. Bulow H., Klein C., Kuehn I., Hollweck R., Nekolla S.G., Schreiber K., Haas F., Böhm J., Schnackenburg B., Lange R., and Schwaiger M. Cardiac magnetic resonance imaging. long term reproducibility of the late enhancement signal in patients with chronic coronary artery disease. Heart 91 (2005) 1158-1163
15. Mahrholdt H., Wagner A., Holly T.A., Elliott M.D., Bonow R.O., Kim R.J., and Judd R.M. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106 (2002) 2322-2327
16. Kim R.J., Wu E., Rafael A., Chen E.L., Parker M.A., Simonetti O., Klocke F.J., Bonow R.O., and Judd R.M. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453